B. Metzler seel. Sohn & Co. AG Buys New Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

B. Metzler seel. Sohn & Co. AG bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 17,199 shares of the company's stock, valued at approximately $752,000.

Several other institutional investors and hedge funds also recently made changes to their positions in RVMD. Vanguard Group Inc. boosted its stake in Revolution Medicines by 14.7% in the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock valued at $747,799,000 after purchasing an additional 2,185,082 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of Revolution Medicines during the third quarter worth $83,082,000. Norges Bank bought a new stake in shares of Revolution Medicines in the fourth quarter valued at about $76,197,000. Pictet Asset Management Holding SA grew its stake in shares of Revolution Medicines by 4,399.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 712,596 shares of the company's stock valued at $31,169,000 after acquiring an additional 696,759 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Revolution Medicines during the fourth quarter worth about $14,067,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on RVMD shares. Needham & Company LLC reissued a "buy" rating and issued a $59.00 price objective on shares of Revolution Medicines in a report on Tuesday. Wedbush reiterated an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a research note on Thursday, February 27th. HC Wainwright raised their price objective on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. UBS Group upped their target price on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus decreased their price target on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Twelve analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $65.23.

Remove Ads

Insider Activity

In other news, COO Margaret A. Horn sold 3,058 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the transaction, the chief operating officer now owns 153,533 shares of the company's stock, valued at approximately $5,993,928.32. This trade represents a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jack Anders sold 1,864 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now directly owns 115,006 shares in the company, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,660 shares of company stock valued at $650,406. 8.00% of the stock is currently owned by corporate insiders.

Revolution Medicines Trading Up 3.2 %

Revolution Medicines stock traded up $1.02 during mid-day trading on Tuesday, reaching $32.42. The company had a trading volume of 690,938 shares, compared to its average volume of 1,421,618. The business has a fifty day simple moving average of $39.42 and a 200 day simple moving average of $45.15. The company has a market cap of $6.03 billion, a P/E ratio of -9.09 and a beta of 1.37. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Research analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.